Antiangiogenic Effect of (±)-Haloperidol Metabolite II Valproate Ester [(±)-MRJF22] in Human Microvascular Retinal Endothelial Cells

Journal of Medicinal Chemistry

Volumn 59, Issue 21, 2016, Pages 9960-9966

  Olivieri, Melania ^a   Amata, Emanuele ^a   Vinciguerra, Shila ^a   Fiorito, Jole ^a   Giurdanella, Giovanni ^a   Drago, Filippo ^a   Caporarello, Nunzia ^a   Prezzavento, Orazio ^a   Arena, Emanuela ^a   Salerno, Loredana ^a   Rescifina, Antonio ^a   Lupo, Gabriella ^a   Anfuso, Carmelina Daniela ^a   Marrazzo, Agostino ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 1 [4 (4 FLUOROPHENYL) 4 HYDROXYBUTYL]PIPERIDIN 4 OL; 4 [4 (4 CHLOROPHENYL) 4 HYDROXYPIPERIDIN 1 YL] 1 (4 FLUOROPHENYL)BUTYL 2 PROPYLPENTANOATE; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; DRUG METABOLITE; HALOPERIDOL; HISTONE DEACETYLASE INHIBITOR; MRJF 22; PENTAZOCINE; PRODRUG; UNCLASSIFIED DRUG; VALPROIC ACID; VASCULOTROPIN A;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD RETINA BARRIER; CAPILLARY ENDOTHELIAL CELL; CELL COUNT; CELL CULTURE; CELL MIGRATION; CELL VIABILITY; CHEMICAL BOND; CONTROLLED STUDY; DRUG CONJUGATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; RAT; RETINA CELL; ANGIOGENESIS; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; ENDOTHELIUM CELL; MICROVASCULATURE; RETINA; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANGIOGENESIS INHIBITORS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; HALOPERIDOL; HUMANS; MICROVESSELS; MOLECULAR STRUCTURE; NEOVASCULARIZATION, PHYSIOLOGIC; RETINA; STRUCTURE-ACTIVITY RELATIONSHIP; VALPROIC ACID;

EID: 84994896328     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b01039     Document Type: Article

References (36)

1. Binu, S.; Soumya, S. J.; Sudhakaran, P. R. Metabolite control of angiogenesis: angiogenic effect of citrate J. Physiol. Biochem. 2013, 69, 383-395 10.1007/s13105-012-0220-9
2. Ellis, L. M.; Fidler, I. J. Angiogenesis and metastasis Eur. J. Cancer 1996, 32A, 2451-2460 10.1016/S0959-8049(96)00389-9
3. Folkman, J.; Shing, Y. Angiogenesis J. Biol. Chem. 1992, 267, 10931-10934
4. Cheung, N.; Mitchell, P.; Wong, T. Y. Diabetic retinopathy Lancet 2010, 376, 124-136 10.1016/S0140-6736(09)62124-3
5. Machein, M. R.; Plate, K. H. Role of VEGF in developmental angiogenesis and in tumor angiogenesis in the brain Cancer Treat. Res. 2004, 117, 191-218 10.1007/978-1-4419-8871-3-13
6. Keeley, E. C.; Mehrad, B.; Strieter, R. M. Chemokines as mediators of tumor angiogenesis and neovascularization Exp. Cell Res. 2011, 317, 685-690 10.1016/j.yexcr.2010.10.020
7. Bulnes, S.; Bengoetxea, H.; Ortuzar, N.; Argandona, E. G.; Garcia-Blanco, A.; Rico-Barrio, I.; Lafuente, J. V. Angiogenic signalling pathways altered in gliomas: selection mechanisms for more aggressive neoplastic subpopulations with invasive phenotype J. Signal Transduction 2012, 2012, 597915 10.1155/2012/597915
8. Choi, S. H.; Lee, H. J.; Jin, Y. B.; Jang, J.; Kang, G. Y.; Lee, M.; Kim, C. H.; Kim, J.; Yoon, S. S.; Lee, Y. S.; Lee, Y. J. MMP9 processing of HSPB1 regulates tumor progression PLoS One 2014, 9, e85509 10.1371/journal.pone.0085509
9. Lupo, G.; Motta, C.; Salmeri, M.; Spina-Purrello, V.; Alberghina, M.; Anfuso, C. D. An in vitro retinoblastoma human triple culture model of angiogenesis: a modulatory effect of TGF-beta Cancer Lett. 2014, 354, 181-188 10.1016/j.canlet.2014.08.004
10. Kerbel, R. S. Tumor angiogenesis N. Engl. J. Med. 2008, 358, 2039-2049 10.1056/NEJMra0706596
11. Mikhail, S.; Bekaii-Saab, T. Maintenance therapy for colorectal cancer: Which regimen and which patients? Drugs 2015, 75, 1833-1842 10.1007/s40265-015-0467-x
12. Grapsa, D.; Syrigos, K.; Saif, M. W. Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer Expert Rev. Anticancer Ther. 2015, 15, 1267-1281 10.1586/14737140.2015.1102063
13. Nguyen, T. T.; Guymer, R. Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration Expert Rev. Clin. Pharmacol. 2015, 8, 541-548 10.1586/17512433.2015.1075879
14. Tojo, N.; Kashiwagi, Y.; Yamamoto, S.; Yamamoto, T.; Yamashita, H. The in vitro response of human retinal endothelial cells to cytokines and other chemically active agents is altered by coculture with vitreous-derived hyalocytes Acta Ophthalmol. 2010, 88, e66-72 10.1111/j.1755-3768.2010.01879.x
15. Collier, T. L.; Waterhouse, R. N.; Kassiou, M. Imaging sigma receptors: applications in drug development Curr. Pharm. Des. 2007, 13, 51-72 10.2174/138161207779313740
16. Martin, W. R.; Eades, C. G.; Thompson, J. A.; Huppler, R. E.; Gilbert, P. E. The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog J. Pharmacol. Exp. Ther. 1976, 197, 517-532
17. Quirion, R.; Bowen, W. D.; Itzhak, Y.; Junien, J. L.; Musacchio, J. M.; Rothman, R. B.; Su, T. P.; Tam, S. W.; Taylor, D. P. A proposal for the classification of sigma binding sites Trends Pharmacol. Sci. 1992, 13, 85-86 10.1016/0165-6147(92)90030-A
18. Maurice, T.; Su, T. P. The pharmacology of sigma-1 receptors Pharmacol. Ther. 2009, 124, 195-206 10.1016/j.pharmthera.2009.07.001
19. Zamanillo, D.; Romero, L.; Merlos, M.; Vela, J. M. Sigma 1 receptor: a new therapeutic target for pain Eur. J. Pharmacol. 2013, 716, 78-93 10.1016/j.ejphar.2013.01.068
20. Colabufo, N. A.; Berardi, F.; Contino, M.; Niso, M.; Abate, C.; Perrone, R.; Tortorella, V. Antiproliferative and cytotoxic effects of some sigma2 agonists and sigma1 antagonists in tumour cell lines Naunyn-Schmiedeberg's Arch. Pharmacol. 2004, 370, 106-113 10.1007/s00210-004-0961-2
21. Vilner, B. J.; John, C. S.; Bowen, W. D. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines Cancer Res. 1995, 55, 408-413
22. Schinina, B.; Martorana, A.; Colabufo, N. A.; Contino, M.; Niso, M.; Perrone, M. G.; De Guidi, G.; Catalfo, A.; Rappazzo, G.; Zuccarello, E.; Prezzavento, O.; Amata, E.; Rescifina, A.; Marrazzo, A. 4-Nitro-2,1,3-benzoxadiazole derivatives as potential fluorescent sigma receptor probes RSC Adv. 2015, 5, 47108-47116 10.1039/C5RA08639F
23. Spruce, B.; Eccles, S.; Dexter, M. Sigma receptor ligands and their medical uses. WO2001074359 A1, 2001.
24. Crottes, D.; Rapetti-Mauss, R.; Alcaraz-Perez, F.; Tichet, M.; Gariano, G.; Martial, S.; Guizouarn, H.; Pellissier, B.; Loubat, A.; Popa, A.; Paquet, A.; Presta, M.; Tartare-Deckert, S.; Cayuela, M. L.; Martin, P.; Borgese, F.; Soriani, O. SigmaR1 regulates membrane electrical activity in response to extracellular matrix stimulation to drive cancer cell invasiveness Cancer Res. 2016, 76, 607-618 10.1158/0008-5472.CAN-15-1465
25. Elmorsy, E.; Elzalabany, L. M.; Elsheikha, H. M.; Smith, P. A. Adverse effects of antipsychotics on micro-vascular endothelial cells of the human blood-brain barrier Brain Res. 2014, 1583, 255-268 10.1016/j.brainres.2014.08.011
26. Bowen, W. D.; Moses, E. L.; Tolentino, P. J.; Walker, J. M. Metabolites of haloperidol display preferential activity at sigma receptors compared to dopamine D-2 receptors Eur. J. Pharmacol. 1990, 177, 111-118 10.1016/0014-2999(90)90260-D
27. Jaen, J. C.; Caprathe, B. W.; Pugsley, T. A.; Wise, L. D.; Akunne, H. Evaluation of the effects of the enantiomers of reduced haloperidol, azaperol, and related 4-amino-1-arylbutanols on dopamine and sigma receptors J. Med. Chem. 1993, 36, 3929-3936 10.1021/jm00076a022
28. Vilner, B. J.; Bowen, W. D. Modulation of cellular calcium by sigma-2 receptors: release from intracellular stores in human SK-N-SH neuroblastoma cells J. Pharmacol. Exp. Ther. 2000, 292, 900-911
29. Marrazzo, A.; Fiorito, J.; Zappala, L.; Prezzavento, O.; Ronsisvalle, S.; Pasquinucci, L.; Scoto, G. M.; Bernardini, R.; Ronsisvalle, G. Antiproliferative activity of phenylbutyrate ester of haloperidol metabolite II [(+/â)-MRJF4] in prostate cancer cells Eur. J. Med. Chem. 2011, 46, 433-438 10.1016/j.ejmech.2010.10.012
30. Sozio, P.; Fiorito, J.; Di Giacomo, V.; Di Stefano, A.; Marinelli, L.; Cacciatore, I.; Cataldi, A.; Pacella, S.; Turkez, H.; Parenti, C.; Rescifina, A.; Marrazzo, A. Haloperidol metabolite II prodrug: Asymmetric synthesis and biological evaluation on rat C6 glioma cells Eur. J. Med. Chem. 2015, 90, 1-9 10.1016/j.ejmech.2014.11.012
31. Slingerland, M.; Guchelaar, H. J.; Gelderblom, H. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors Anti-Cancer Drugs 2014, 25, 140-149 10.1097/CAD.0000000000000040
32. Blaheta, R. A.; Michaelis, M.; Driever, P. H.; Cinatl, J., Jr. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies Med. Res. Rev. 2005, 25, 383-397 10.1002/med.20027
33. Michaelis, M.; Doerr, H. W.; Cinatl, J., Jr. Valproic acid as anti-cancer drug Curr. Pharm. Des. 2007, 13, 3378-3393 10.2174/138161207782360528
34. Zhao, Y.; You, W.; Zheng, J.; Chi, Y.; Tang, W.; Du, R. Valproic acid inhibits the angiogenic potential of cervical cancer cells via HIF-1alpha/VEGF signals Clin. Transl. Oncol. 2016, 18, 1123-1130 10.1007/s12094-016-1494-0
35. Yamanegi, K.; Kawabe, M.; Futani, H.; Nishiura, H.; Yamada, N.; Kato-Kogoe, N.; Kishimoto, H.; Yoshiya, S.; Nakasho, K. Sodium valproate, a histone deacetylase inhibitor, modulates the vascular endothelial growth inhibitor-mediated cell death in human osteosarcoma and vascular endothelial cells Int. J. Oncol. 2015, 46, 1994-2002 10.3892/ijo.2015.2924
36. Romeo, R.; Carnovale, C.; Giofre, S. V.; Chiacchio, M. A.; Garozzo, A.; Amata, E.; Romeo, G.; Chiacchio, U. C-5′-Triazolyl-2′-oxa-3′-aza-4′a-carbanucleosides: Synthesis and biological evaluation Beilstein J. Org. Chem. 2015, 11, 328-334 10.3762/bjoc.11.38